<DOC>
	<DOCNO>NCT01296243</DOCNO>
	<brief_summary>Given activity docetaxel patient progressive , metastatic castration-resistant prostate cancer , study undertaken evaluate activity tesetaxel , orally bioavailable taxane , chemotherapy-naive chemotherapy-exposed patient .</brief_summary>
	<brief_title>Tesetaxel Chemotherapy-naive Patients With Progressive , Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Key At least 18 year age Histologically confirm prostate cancer , currently progressive disease Evidence metastatic disease Castrate level testosterone ( &lt; 50 ng/dL ) Eastern Cooperative Oncology Group performance status 0 1 Chemotherapyna√Øve Adequate bone marrow , hepatic , renal function Ability swallow oral soliddosage form medication Key History presence brain metastasis leptomeningeal disease Operable cancer Uncontrolled diarrhea Uncontrolled nausea vomit Known malabsorptive disorder Currently active second malignancy nonmelanoma skin cancer Human immunodeficiency virus ( HIV ) infection base history positive serology Significant medical disease cancer Presence neuropathy &gt; Grade 2 ( National Cancer Institute Common Toxicity Criteria [ NCI CTC ] ; v4.0 ) Need anticancer treatment Need continue regularlytaken medication potent inhibitor inducer CYP3A pathway Pglycoprotein activity Less 2 week since use medication ingestion agent , beverage , food potent inhibitor inducer CYP3A pathway Pglycoprotein activity Less 4 week since use another investigational agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Castration-resistant prostate cancer</keyword>
	<keyword>Tesetaxel</keyword>
	<keyword>Taxanes</keyword>
	<keyword>Chemotherapy-naive</keyword>
	<keyword>Chemotherapy-exposed</keyword>
	<keyword>Progressive , metastatic castration-resistant prostate cancer</keyword>
</DOC>